Search
cilgavimab/tixagevimab (Evusheld, AZD7442)
Indications:
- combination used for pre-exposure prevention of Covid-19
* reduces symptomatic Covid-19 by 83% [3]
Dosage:
- two gluteal 300 mg (3 mL) intramuscular injections of cilgavimab & tixagevimab
* cilgavimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial
* tixagevimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial
* one hour observation period after injections
* a negative SARS-CoV2 RNA test 5 days prior to administration
* at least 2 weeks after Covid-19 vaccine
Adverse effects:
- fatigue
- edema
- headache
- cough
- potentially serious:
- chest pain
- pain or discomfort in one or both arms, the back, neck, jaw or stomach
- dyspnea
- cold sweat
- nausea
- lightheadedness
Mechanism of action:
- combination of monoclonal antibodies specifically directed against the spike protein of SARS-CoV2
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
monoclonal antibody to spike glycoprotein of SARS-CoV2 (COVID-19)
References
- MedlinePlus: Tixagevimab and Cilgavimab
https://medlineplus.gov/druginfo/meds/a621058.html
- Berg S
3 tips for doctors on using Evusheld for COVID-19 protection.
AMA Public Health. April 14, 2022
https://www.ama-assn.org/delivering-care/public-health/3-tips-doctors-using-evusheld-covid-19-protection
- Levin MJ et al.
Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19.
N Engl J Med 2022 Apr 20; [e-pub].
https://www.nejm.org/doi/10.1056/NEJMoa2116620
- HIGHLIGHTS OF EMERGENCY USE AUTHORIZATION (EUA)
Evusheld (tixagevimab) injection; (cilgavimab) injection, co-packaged for
intramuscular use.
https://www.fda.gov/media/154701/download